These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Therapeutic Prime/Pull Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein and CXCL11 Chemokine Boosts Antiviral Local Tissue-Resident and Effector Memory CD4 Quadiri A; Prakash S; Dhanushkodi NR; Singer M; Zayou L; Shaik AM; Sun M; Suzer B; Lau L; Chilukurri A; Vahed H; Schaefer H; BenMohamed L bioRxiv; 2023 Aug; ():. PubMed ID: 37609157 [TBL] [Abstract][Full Text] [Related]
8. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination. Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763 [TBL] [Abstract][Full Text] [Related]
9. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309 [TBL] [Abstract][Full Text] [Related]
10. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545 [TBL] [Abstract][Full Text] [Related]
11. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802 [TBL] [Abstract][Full Text] [Related]
14. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. Awasthi S; Huang J; Shaw C; Friedman HM J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells. Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620 [TBL] [Abstract][Full Text] [Related]
17. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8 Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250 [TBL] [Abstract][Full Text] [Related]
18. Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4 Bourne N; Perry CL; Banasik BN; Miller AL; White M; Pyles RB; Schäfer H; Milligan GN J Virol; 2019 Feb; 93(4):. PubMed ID: 30463981 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834 [TBL] [Abstract][Full Text] [Related]
20. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]